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15331 In witm Activity of Oral Cephalosporins: 
A Comparative Review 
D. F e h g h a m .  GR Micro Lid, London, UK 
Chemical mocLfcations to the cephalosporin (cephem) nucleus have 
produced very many compounds of this class of antimicrobials 
which dSer in spectrum of antibacterial activity and pharmacoki- 
netic properties. A general classlfication of the compounds into first, 
second and third generation molecules largely reflects their stabil- 
ity to B-lactamase degradation and, hence, their improved activity 
against Gram negative species, particularly those of the Enterobac- 
teriaceae, with thlrd generation compounds genedy the most po- 
tent. Originally, the more active cephalosporins were available for 
parented adrmnistration, only However, during the last decade, a 
number of orally active third generation cephalosporins have be- 
come available either as pro-drugs (e.g. cefpodoxime and cefe- 
tamet) or those which are absorbed intact (e.g. cefixime, cefdbuten 
and cefdinir). For some of these molecules improved stability to 
p-lactamases has been gained at the expense of anti-Gram posi- 
tive activity (e.g. cefixime, ceftibuten, cefetamet) whilst some are 
characterised by stability to p-lactamases typical of h d  genera- 
tion compounds and retained activity against Gram positive species 
similar to second generation cephalosporins (e.g. cefdmir, cefpo- 
doxime). In this review, the activity of cefdinir, cefpodoxime, ce- 
fixime, ceftibuten and cefetamet (third generation cephalosporins) is 
compared with that of cefaclorAoracarbef, cefuroxime, and cefprozil 
(second generation cephalosporins) and cephaleldn (first generation 
cephalosporin) against a range of Gram positive and Gram negative 
bacterial pathogens causing infections in important therapeutic areas. 
Pharmacokinetic, Phannacodynamic, and Efficacy 
Considerations in Oral Cephalosporin Therapy 
Selection 
D.F! Nicolau. Harfford Hospital, Hartjord, C7; USA 
Over the last decade, much has been learned concerning the com- 
plex interaction of the host-drug-pathogen triad. Based on our cur- 
rent understanding of antimicrobial pharmacodynamics or the cor- 
relation of drug concentration and the clinical effect (e.g., bacterial 
killing) observed with the major classes of antimicrobials optimal 
administration techniques can be designed to maximize bactericidal 
activity. However, the clinician must remember that the administra- 
tion technique used to maximize antibacterial activity is very dif- 
ferent depending on drug class. The pharmacodynamic properties 
of a spechc antibiotic are therefore, an integration of two related 
areas, microbiologic activity and pharmacokmetics. According, it is 
not correct to choose antibiotics based solely on their microbiologic 
activity or pharmacokmetics, rather selection should based on their 
individual pharmacodynamic profiles. The application of these re- 
cent findings provides the opportunity to utilize antimicrobials in a 
manner which promotes maximal efficacy, while reducing the risk 
of drug toxicity. 
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Cefdinir (CDR) is an extended-spectrum oral cephalosporin that 
is active against pathogens commonly seen in ABS, includmg S. 
pneumoniae, H. injuenzae, and M .  ratarrhalis. Two randomized, 
investigator blind, multicenter trials (one in the U.S., one in Europe) 
compared 2 doses of CDR (600 mg qd x 10 days and 300 mg 
bid x 10 days) to amoxicillin/clavulanate (A/C) (500 tid x 10 
days) in adult and adolescent patients with ABS. Twelve hundred 
twenty-nine patients entered the US. study, 698 with antral 
puncture; 569 patients entered the European study, all with antral 
puncture. Clinical response (cure or improvement) was determined 
7 to 14 days and 3-5 weeks post-therapy. Microbiologic eradication 
rates were determined 10 to 30 days post-therapy in a subset of 
patients with pre- and post-therapy sinus aspirate culture. Rates of 
adverse events were examined. CDR, given once or twice daily, was 
as effective chically (- 90% cure rate) as A/C given 3 times daily 
in the treatment of ABS. Microbiologic eradication rates were also 
similar in the 3 groups. CDR caused less adverse events requiring 
treatment discontinuation. 
Rational Oral Cephalasporin Use in the Clinical 
Practice Setting 
G.D. Campbell. USA 
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Serious Infection: Cutrent Challenges and Future 
Approaches 
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Noffingham, NG5 IPB, UK 
The relationship between man and the microbd environment is 
delicately balanced. Despite more than half a century of antimi- 
crobd chemotherapy, infectious diseases remain a major problem, 
often changing in response to the expandmg elderly population, 
advances in medicine and other ecological pressures. Drug develop- 
ment has reached an impressive scale of sophistication; automated 
screening programmes, combinatorial chemisq and sophisticated 
structure-activity approaches have yielded new molecules, while new 
molecular targets are anticipated fiom gene mapping approaches. Mi- 
cro-organisms may m e r  less in their susceptibility than in their vir- 
ulence expression, which could be important at a time of increasing 
drug resistance. Serious lower respiratory tract infections in the hos- 
pitahsed patient - an important model for discussing these issues - is 
often currently managed with a broad spectrum cephalosporin, car- 
bapenem or quinolone. Predicting outcome is not solely a function 
of susceptibility but also needs to include considerations of pharma- 
